CT-109-CAR-T

N/A

Report date: 2025/01/26 17:08:15

Base Information

Drug NameCT-109-CAR-T

Drug Alias Nameanti-CEACAM-5/6 CAR T-cell therapy (Stromatis)CT-109-CAR-T

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 6 modulatorsCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5Carcinoembryonic antigen related cell adhesion molecule 6

Therapy Area/IndicationsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesStromatis Pharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesStromatis Pharma Inc

Inactive CompaniesN/A

Active IndicationsCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A